India’s drug regulator has given a new eye drug to green byte which can slow down the progress of Myopia in children between the ages of 6 to 12, which is also known as a close vision.

The Central Drugs Standard Control Organization (CDSCO) has provided marketing approval to ante pharmaceuticals for a new formulation of eye drops, which marks the first global regulatory approval for this specific strength specifically designed for pediatric use.

Treatment will only be available on the prescription, and only after evaluating an eye specialist and confirms that a child is suitable for therapy.

What is Myopia?

Myopia is a clinical name for near-vision, which means that when one can clearly see nearby objects, they have difficulty looking at the objects. The problem is very common, not only in India but around the world. Not treating yourself can affect your vision in a long time, causing headaches, eye stress, and squinting.

The causes of myopia are not specific because it is a mixture of hereditary factors and lifestyle options. Working very close to your eyes and seeing an object for a long time can lead to myopia.

It can be managed with glasses, contact lenses or surgery.

One of the leading investigators of the Indian clinical testing, Dr. Tirupati Eye Center and Research Institute Medical Director Dr. Mohita Sharma said that approval is on time, as India is watching a rapid growth in childhood matters of Myopia.

He said that children are spending more time on the screen and are doing activities that they need to focus on the same object for a long time, both are associated with the deteriorating eyesight.

“Myopia is becoming a serious public health concern. This new treatment is a success in pediatric eye care. It can help slow down myopia and prevent future complications related to high myopia,” Dr. Sharma said.

The drug was cleaned after the successful phase 3 clinical trials and a rigorous regulatory process in India.

According to Antode Pharmaceuticals, the rate of Myopia in India has increased considerably in the last two decades, with 4% to about 25% in 1999 today. Some studies predict that by 2050, one of every two children in the country can be affected.

“This approval shows our commitment to innovation and commitment to addressing the increasing challenges in eye health,” said Masurkar of Antode CEO Nikkhik.